All Stories

Takeda looks toward 'inflection point' as it eyes new launches to shake off Vyvanse generic impacts

The company has three key phase 3 readouts this year, which it hopes will contribute to long-term growth despite a flat outlook for 2025.

May 8, 2025 - 16:21
 0
Takeda looks toward 'inflection point' as it eyes new launches to shake off Vyvanse generic impacts
The company has three key phase 3 readouts this year, which it hopes will contribute to long-term growth despite a flat outlook for 2025.
Read More

Tags:

Previous Article

VAG Nuremberg’s hundredth electric bus is one of a total of 31 new Mercedes-Benz...

Next Article

NIH grant terminations under Trump have totaled at least $1.8 billion, analysis ...

Related Posts

Sanofi and McLaren Racing drive full speed ahead to bring meningitis awareness to the racetrack

Sanofi and McLaren Racing drive full speed ahead to bri...

May 2, 2025  0

Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch'

Daiichi Sankyo, AstraZeneca's highly touted ADC Datrowa...

Apr 28, 2025  0

Vertex, with new launches gaining steam, boosts revenue forecast despite Trikafta dilemma in Russia

Vertex, with new launches gaining steam, boosts revenue...

May 6, 2025  0